Risk of Restenosis and Health Status Outcomes for Patients Undergoing Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery

John A. Spertus, MD, MPH; Ravi Nerella, MD; Richard Kettlekamp, MD; John House, MS; Steve Marso, MD; A. Michael Borkon, MD; John S. Rumsfeld, MD, PhD

Background—Previous comparisons of percutaneous coronary interventions (PCIs) and coronary artery bypass graft (CABG) surgery have demonstrated similar survival but have also generally found better health status outcomes (symptoms, function, and quality of life) with CABG. The principal limitation of PCI has been the occurrence of restenosis. No previous studies comparing the health status outcomes of PCI and CABG have examined differences in these outcomes as a function of patients’ preprocedural risk for restenosis.

Methods and Results—We examined the health status outcomes, using the Seattle Angina Questionnaire (SAQ), among 1459 consecutive patients (1027 treated with PCI and 432, with CABG), stratified by their risk for restenosis. In multivariable-adjusted, linear regression analyses, no differences in 1-year angina or quality of life were observed among the 37.4% of patients at low risk for restenosis. However, among the 46.7% at intermediate risk for restenosis, 1-year health status scores were moderately better after CABG surgery compared with PCI (difference in SAQ angina frequency scores favoring CABG 6.1 ± 1.7 points, P=0.0003; difference in SAQ quality of life 5.8 ± 1.6 points, P=0.0004). Even larger differences in 1-year outcomes favoring CABG surgery were observed in patients at high risk for restenosis (SAQ angina frequency difference 10.8 ± 4.2, P=0.01; SAQ quality of life difference 10.8 ± 3.9, P=0.006).

Conclusions—The relative health status benefits of CABG surgery compared with PCI increase as the risk of restenosis increases. Although selecting CABG or PCI is complex, preprocedural restenosis risk should be considered. It should also be tested as a means for considering drug-eluting as opposed to bare metal stents in PCI. (Circulation. 2005;111: 768-773.)

Key Words: angioplasty • bypass • restenosis • quality of life

Numerous studies have compared the outcomes of coronary revascularization between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. Although most studies have found no differences in survival or nonfatal myocardial infarction, they have consistently shown that patients who undergo PCI are more likely to have recurrent angina and to require repeat procedures.1-5 Also, because the elimination of angina is more complete with surgery, patients may derive a greater quality-of-life benefit with CABG compared with PCI.6-8 The principal reason for recurrent angina and repeat procedures after PCI appears to be the development of restenosis. For example, in the recent Stent or Surgery trial, 6-month angina frequency scores were significantly better among patients treated with CABG surgery overall, but no difference was seen in the subset of PCI patients who did not have a repeat procedure.9 Similarly, an observational registry identified that patients who underwent surgical revascularization had better symptom control and quality of life and that most of this difference was attributable to PCI patients who required a repeat procedure.10

If the health status (ie, angina and quality of life) benefits of CABG surgery are most evident in those PCI patients who develop clinical restenosis, then it is reasonable to consider preferential referral of patients at high risk of restenosis to CABG surgery. Currently, however, no data demonstrate that preprocedural risk for restenosis is associated with differences in outcomes between CABG surgery and PCI.

We examined the differences in health status outcomes between CABG surgery and PCI among a prospective cohort of consecutive patients undergoing coronary revascularization. Using a previously reported clinical risk score to stratify patients into categories of low, intermediate, and high risk for restenosis,11 we examined the differences in 1-year health status among those treated surgically and those treated with PCI. Establishing clinically meaningful differences in patient
outcomes among patients at higher risk for restenosis could support more efficient treatment selection in such patients.

Methods

Study Sample

Data were prospectively collected from a consecutive series of patients undergoing coronary revascularization at the Mid America Heart Institute in Kansas City, Mo. The purpose of this study was to describe the health status of patients before and 1 year after coronary revascularization. The details of patient recruitment have been previously described. In brief, from February 1999 to August 2000, all patients undergoing coronary revascularization were approached to participate in the study. Among all 3669 patients who underwent PCI or CABG during the time period, 29 (0.8%) were urgent cases and died during the procedure, 78 (2%) were non–English speaking, 1079 (29%) refused to participate, and only 162 (4.4%) were missed. All patients who consented were administered a series of health status questionnaires at baseline and at follow-up, and these data independently demonstrated to be valid, reproducible, sensitive to

Clinical

Prior revascularization

Current smoker

Hypertension

History of cerebrovascular disease

Family history of CAD

Creatinine ≥2.0

Left main CAD

Chronic obstructive pulmonary disease

Diabetes

Ejection fraction <40%

Preprocedural restenosis risk

Low (score <4)

Intermediate (score 4–8)

High (score >8)

Baseline health status

SAQ angina frequency

SAQ quality of life

1-Year health status characteristics

SAQ angina frequency

SAQ quality of life

Values are n (%) or mean±SD. CAD indicates coronary artery disease.

Clinical and Procedural Assessments of Disease Severity

The Mid America Heart Institute has maintained a procedural database for patients undergoing coronary interventions since 1982. This database provides a comprehensive description of coronary anatomy, technique of revascularization, procedural results, and complications. It is compatible with American College of Cardiology13 and Society of Thoracic Surgeons14 data definitions.

Outcome Assessment

Angina frequency and quality of life were measured with the Seattle Angina Questionnaire (SAQ), a 19-item, disease-specific measure for patients with coronary artery disease. Each SAQ domain has been independently demonstrated to be valid, reproducible, sensitive to

<table>
<thead>
<tr>
<th>Table 1. Baseline Patient Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
</tr>
<tr>
<td>Sociodemographic</td>
</tr>
<tr>
<td>Age, y</td>
</tr>
<tr>
<td>Sex (male)</td>
</tr>
<tr>
<td>Race (white)</td>
</tr>
<tr>
<td>Body mass index</td>
</tr>
<tr>
<td>Clinical</td>
</tr>
<tr>
<td>Prior revascularization</td>
</tr>
<tr>
<td>Current smoker</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>History of cerebrovascular disease</td>
</tr>
<tr>
<td>Family history of CAD</td>
</tr>
<tr>
<td>Creatinine ≥2.0</td>
</tr>
<tr>
<td>Left main CAD</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Ejection fraction &lt;40%</td>
</tr>
<tr>
<td>Preprocedural restenosis risk</td>
</tr>
<tr>
<td>Low (score &lt;4)</td>
</tr>
<tr>
<td>Intermediate (score 4–8)</td>
</tr>
<tr>
<td>High (score &gt;8)</td>
</tr>
<tr>
<td>Baseline health status</td>
</tr>
<tr>
<td>SAQ angina frequency</td>
</tr>
<tr>
<td>SAQ quality of life</td>
</tr>
<tr>
<td>1-Year health status characteristics</td>
</tr>
<tr>
<td>SAQ angina frequency</td>
</tr>
<tr>
<td>SAQ quality of life</td>
</tr>
</tbody>
</table>
TABLE 2. Clinical Restenosis Risk Model

<table>
<thead>
<tr>
<th>Clinical Variable</th>
<th>Risk Points Assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myocardial infarction (STEMI patients)</td>
<td>4</td>
</tr>
<tr>
<td>undergoing primary PCI</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>4</td>
</tr>
<tr>
<td>Daily angina (SAQ angina frequency score ≤30)</td>
<td>3</td>
</tr>
<tr>
<td>Age &lt;55 y</td>
<td>3</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>2</td>
</tr>
<tr>
<td>Weekly/monthly angina (SAQ angina frequency</td>
<td>2</td>
</tr>
<tr>
<td>score 31–90)</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>2</td>
</tr>
<tr>
<td>Multivessel coronary artery disease</td>
<td>1</td>
</tr>
</tbody>
</table>

STEMI indicates ST-segment-elevation myocardial infarction.

clinical change, and prognostic of subsequent death and acute coronary syndromes.17–19 The angina frequency and quality-of-life scales range from 0 to 100, where higher scores indicate fewer symptoms and better quality of life.

Restenosis Risk Model

A recently developed restenosis risk model was used to categorize each patient’s risk for clinical restenosis, defined as a repeat procedure within the next year to the target vessel of the original procedure.11 The goal in creating the restenosis risk model was to use clinical data that could be readily obtained before PCI and therefore used to inform risk stratification before the procedure. Using logistic regression, with the development of clinical restenosis as the dependent variable, we applied a univariate screen to a wide array of candidate demographic, cardiac, and noncardiac predictor variables. Variables with a univariate probability value <0.10 were considered in the multivariable model. The final risk model was developed by forward stepwise regression, with retention of those predictors that were independently associated with restenosis (P<0.05). Its c statistic was 0.65, and the model had good calibration (Hosmer-Lameshow P=1.0), suggesting no significant differences across the range of predicted restenosis rates.

To facilitate clinical application, each predictor was given an approximately linear score weighted by its individual β coefficient in the logistic model. Those predictor variables with β coefficients >0.6 were assigned 4 points, those with coefficients of 0.5 to 0.6 were assigned 3 points, those with coefficients of 0.3 to 0.5 were assigned 2 points, and significant predictors with coefficients <0.3 were given 1 point. The final model included 8 clinical characteristics (Table 2) and assigned 4 scores were observed. Coronary stents were used in 83% of the PCI procedures.

After 1-year of follow-up, significantly more patients treated with PCI required a repeat revascularization procedure (26% versus 2%, P<0.0001). Overall, at 1 year, CABG surgery patients had significantly less angina compared with PCI patients (1-year SAQ angina frequency scores of 96±12.9 versus 91.3±18.9, P<0.001). They were less likely to have had a prior revascularization procedure or cerebrovascular disease. No differences in baseline SAQ angina frequency or quality-of-life scores were observed. Coronary stents were used in 83% of the PCI procedures.

Univariate 1-Year Health Status by Procedure, Stratified by Preprocedural Restenosis Risk

Angina frequency and quality-of-life scores at 1 year were compared in patients who received CABG surgery versus PCI within each stratum of preprocedural restenosis risk. Overall, 37.4% of the patients were classified as being at low risk, 46.7% at intermediate risk, and 16.1% at high risk for restenosis. Among those at low risk for restenosis, no significant differences in 1-year angina frequency (96.5±1 versus 95.5±0.5, P=0.38) or quality-of-life (91.3±1.1 versus 90.3±0.7, P=0.40) scores were found between those treated with CABG surgery and those treated with PCI.
or quality of life (difference=0.5±1.5 point, \(P=0.73\)) scores.

Among intermediate-risk patients, angina frequency (difference=6.1±1.7 points, \(P=0.0003\)) and quality-of-life (difference=5.8±1.6 points, \(P=0.0004\)) scores were significantly better after CABG surgery. Even greater differences favoring CABG were observed in the group at highest risk for restenosis. In these patients, the adjusted 1-year angina frequency scores were 10.8±4.2 points higher (\(P=0.01\)), and the adjusted SAQ quality-of-life scores were 10.8±3.9 points higher favoring CABG surgery (\(P=0.006\)).

### Restricted Analyses in Those With Multivessel Coronary Disease

Because patients with single-vessel disease may not be ideal candidates for CABG surgery, we repeated the analyses only in those with multivessel coronary disease. Among the 676 PCI patients and 410 CABG patients with multivessel disease, similar results were found when comparing 1-year health status outcomes by stratum of restenosis risk.

Among the patients at the lowest risk of restenosis, no differences in angina frequency (100±3.7 versus 100±3.9, \(P=0.92\)) or quality-of-life (86.6±4.5 versus 87.5±4.8, \(P=0.60\)) outcomes were observed. In the intermediate-risk group, patients who underwent CABG surgery had significantly more angina relief (angina frequency score of 97.1±8.9 versus 91.4±9.1, \(P=0.001\)) and better quality of life (92.1±8.6 versus 87.3±8.7; \(P=0.004\)) than did PCI-treated patients. Among the patients at highest risk for restenosis, even larger differences in outcome were seen in favor of the CABG-treated patients. In this group, the angina frequency score was 94.4±10.2 for patients treated with CABG surgery compared with 83.4±10.5 for those who received PCI (\(P=0.01\)). The 1-year quality-of-life scores were 86.4±9.5 and 76.3±9.8, respectively (\(P=0.01\)).

### Discussion

This study found a significant relationship between the preprocedural risk of restenosis and the relative benefits of CABG surgery compared with PCI with respect to patients’ 1-year health status (angina frequency and quality of life) outcomes. We found no difference between CABG surgery and PCI for 1-year angina frequency or quality of life among patients at low risk for restenosis. However, in patients at intermediate risk for restenosis, CABG surgery was associated with significantly less angina and better quality of life. Among the patients at high risk for restenosis, even larger differences in 1-year angina and quality of life in favor of CABG surgery were observed. These results were consistent for analyses restricted to patients with multivessel coronary artery disease. Therefore, this study suggests that patients with moderate to high risk of restenosis have better health status outcomes with CABG surgery and that it may be reasonable to preferentially consider surgical revascularization for these patients.

Multiple randomized trials have demonstrated equivalent mortality after CABG surgery and PCI,\(^1,2,4,5,20\) while one has suggested a survival advantage for surgery.\(^3\) Because mortality outcomes are fairly similar, it is important to examine other patient outcomes, particularly patient-reported health

---

A, Adjusted 1-year SAQ angina frequency scores. Adjusted mean angina frequency scores 1 year after CABG and PCI are provided for each stratum of restenosis risk. B, Adjusted 1-year SAQ quality-of-life scores. Adjusted mean quality-of-life scores 1 year after CABG and PCI are provided for each stratum of restenosis risk.

Among patients in the intermediate restenosis risk group, however, greater angina relief was achieved for those patients undergoing CABG surgery compared with those treated with PCI (96.5±1.1 versus 90.3±0.8, \(P<0.001\)). One-year quality of life was also better among intermediate-risk patients treated with CABG surgery (90.7±1.1 versus 84.9±0.8, \(P=0.001\)) and better quality of life (92.1±8.6 versus 87.3±8.7; \(P=0.004\)) than did PCI-treated patients. Among the patients at highest risk for restenosis, even larger differences in outcome were seen in favor of the CABG-treated patients. In this group, the angina frequency score was 94.4±10.2 for patients treated with CABG surgery compared with 83.4±10.5 for those who received PCI (\(P=0.01\)). The 1-year quality-of-life scores were 86.4±9.5 and 76.3±9.8, respectively (\(P=0.01\)).

### Multivariable 1-Year Health Status by Procedure, Stratified by Preprocedural Restenosis Risk

After controlling for age, sex, body mass index, hypertension, renal insufficiency, history of cerebrovascular disease, family history of coronary artery disease, the presence of unstable angina, left main coronary artery disease, and the presence of an ejection fraction <40%, the results of the univariate analyses were maintained. The Figure provides the risk-adjusted, 1-year angina frequency and quality-of-life scores for CABG and PCI patients by preprocedural risk of restenosis.

Among the patients at lowest risk for restenosis, there were no significant differences between patients who underwent CABG surgery versus PCI in 1-year angina frequency (difference in scores favoring CABG=0.8±1.3 point, \(P=0.51\))...
status (symptom burden and quality of life), because differ-ences in these outcomes may help guide the choice of therapy. Although it has been shown that both CAGB surgery and PCI can improve health status outcomes, there have been few head-to-head comparisons, and the results have been inconsistent. Previous studies either have found equivalent health status outcomes or have favored CAGB surgery, linked to less angina and fewer repeat procedures. Interest-ingly, although restenosis is the proposed mechanism for the potential differences in health status outcomes, to our knowl-edge, no one has previously evaluated health status outcomes after CAGB surgery versus PCI stratified by restenosis risk. These are the first data to demonstrate that a relatively simple risk stratification tool can identify patients who may prefer-entially benefit from CAGB surgery compared with PCI. In particular, although we found no difference in the 1-year health status outcomes among those with the lowest risk of restenosis, CAGB surgery provided better average health status among patients with moderate and high preprocedural risks of restenosis.

The availability of drug-eluting stents is an important consideration in the interpretation of these data. At the time of this registry, only bare metal stents were available. Several recent clinical trials have demonstrated the superiority of drug-eluting stents in preventing restenosis compared with bare metal stents. For example, in the RAVEL trial (RAandomized study with the sirolimus-eluting Bx VElocity balloon-expandable stent), no episodes of significant resteno-sis occurred among patients treated with a sirolimus-eluting stent compared with a restenosis rate of 28.8% in the bare metal stent group. In the SIRIUS trial (SIroImUS-coated stent in patients with de novo coronary artery lesions), rates of 4.1% versus 16.6% were observed. The costs of drug-eluting stents are substantially higher than those of bare metal stents, however. If one presumes that the differences in outcomes observed in this study are due to restenosis after PCI and that the use of drug-eluting stents would produce outcomes as good as those observed after CAGB surgery, then these results suggest that little clinical benefit would be obtained with the use of drug-eluting stents in the population of patients at low risk for restenosis. Conversely, among those at high restenosis risk, substantial benefit would likely be observed. As providers seek to develop a rational strategy for the adoption of expensive new technologies like drug-eluting stents, risk-stratification approaches such as the one supported by the results of this study may form the founda-tion for the cost-effective allocation of such therapies.

Several potential limitations of this study are worth noting. First, the population used to develop the restenosis risk model was the same population in which we conducted these analyses. Furthermore, the discriminative ability of our resteno-sis risk model was only modest. Predicting restenosis in patients undergoing PCI has been a subject of great investiga-tive interest. The most recently published model, using a more complex set of preprocedural variables from 1312 patients in the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) database, reported a c statistic of only 0.63. Our model was slightly better, is easier to implement, and was derived from a larger dataset. Although better models to predict restenosis are needed, we would expect inaccuracies in predicting restenosis to bias our results to the null hypothesis. Finding clinically significant outcomes dif-fferences by using an imperfect model underscores the potential of risk stratification, based on risk of restenosis, to select a patient’s revascularization strategy. Future investigators should validate this model in different populations and determine whether the clinically significant differences in outcomes that we observed are present. Second, we did not collect data about the costs of therapy. Because the implica-tions of our findings about the triage of therapy have direct implications for the costs of care, quantifying this important outcome is critical for future work. A third limitation is our loss to follow-up. Although we found no selection bias by propensity scores for missing data, we cannot completely exclude this possibility. Finally, this is an observational study, so it is possible that unmeasured clinical factors may account for the differences in observed outcomes between CAGB and PCI. In this regard, multivariable models were used to address confounding due to measured factors, and multivariable results were consistent with the unadjusted analyses.

In conclusion, we have documented a significant relation-ship between the preprocedural risk of restenosis and both the control of angina and patients’ quality of life 1 year after revascularization. Selecting an optimal mode of coronary revascularization is a complex process that needs to incorpo-rate a number of clinical factors, technical considerations, and patient preferences. However, using health status outcomes as part of clinical decision making is an important step forward in tailoring treatment recommendations to how such treat-ments will affect patients’ lives. By using a simple scoring algorithm that can be generated at the time of coronary angiogram, without the need for complex angiographic mea-surements, treatment recommendations tailored to individual patient’s likelihood of durable procedural success can be made. Future testing of this approach for the triage of CAGB surgery versus PCI and/or drug-eluting versus bare metal stents is warranted.

Acknowledgment
Dr Rumsfeld is supported by a VA Health Services Research Advanced Research Career Development Award (98341-2).

References


Risk of Restenosis and Health Status Outcomes for Patients Undergoing Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery
John A. Spertus, Ravi Nerella, Richard Kettlekamp, John House, Steve Marso, A. Michael Borkon and John S. Rumsfeld

_Circulation_. 2005;111:768-773; originally published online February 7, 2005; doi: 10.1161/01.CIR.0000155242.70417.60
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/111/6/768

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/